# CAR T Cell Therapy Related Cardiovascular Outcomes

> **NCT05130489** · — · COMPLETED · sponsor: **University College London Hospitals** · enrollment: 150 (actual)

## Conditions studied

- Cardiovascular Diseases
- B-cell Acute Lymphoblastic Leukemia
- B-cell Lymphoma Refractory
- B-cell Lymphoma Recurrent
- Primary Mediastinal Large B-cell Lymphoma (PMBCL)
- Diffuse Large B Cell Lymphoma
- Cardiotoxicity
- Cardiovascular Complication

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05130489
- **Lead sponsor:** University College London Hospitals
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-18
- **Primary completion:** 2023-03-01
- **Final completion:** 2023-05-01
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2023-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05130489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05130489, "CAR T Cell Therapy Related Cardiovascular Outcomes". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05130489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*